ConductScience.org, home

Paper6366128

Phase I study of carboplatin given on a five-day intravenous schedule.

Rozencweig M and 6 others. J Clin Oncol, 1983. Cited by 65 papers, by iCite.

Cite this record

ConductScience Library. Phase I study of carboplatin given on a five-day intravenous schedule. Papers, record 6366128. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6366128

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase I study of carboplatin given on a five-day intravenous schedule.
PubMed
Journal
J Clin Oncol
PubMed
Year
1983
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
65
iCite
Relative citation ratio, by iCite
3.16
iCite
Revised in PubMed
2022-03-31
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rozencweig MM
2Nicaise CC
3Beer MM
4Crespeigne NN
5Van Rijmenant MM
6Lenaz LL
7Kenis YY

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
NeoplasmsMajor topic
Organoplatinum CompoundsMajor topic
Adult
Aged
Carboplatin
Drug Administration Schedule
Drug Evaluation
Female
Hematologic Diseases
Humans
Infusions, Parenteral
Kidney Diseases
Male
Middle Aged

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
N01-CM 53840NCI NIH HHSUnited StatesN01CM053840PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.

PMIDTitleJournalYearIn PapersSource
30666153Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study.Breast Cancer (Dove Med Press)2019https://conductscience.org/library/papers/30666153PubMed
26061351Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry.Drug Test Anal2015https://conductscience.org/library/papers/26061351PubMed
24234333Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study.Tumour Biol2014https://conductscience.org/library/papers/24234333PubMed
9738983Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro.Jpn J Cancer Res1998https://conductscience.org/library/papers/9738983PubMed
9247610Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule.Jpn J Cancer Res1997https://conductscience.org/library/papers/9247610PubMed
8431374A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.Br J Cancer1993https://conductscience.org/library/papers/8431374PubMed
8258189Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8258189PubMed
6392147A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.Invest New Drugs1984https://conductscience.org/library/papers/6392147PubMed
3525449A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study).Invest New Drugs1986https://conductscience.org/library/papers/3525449PubMed
3516429High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3516429PubMed
2679841Acute and cumulative effects of carboplatin on renal function.Br J Cancer1989https://conductscience.org/library/papers/2679841PubMed
2650904Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2650904PubMed
2649354Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.Drugs1989https://conductscience.org/library/papers/2649354PubMed
2191847Antineoplastic drugs in 1990. A review (Part II).Drugs1990https://conductscience.org/library/papers/2191847PubMed
2183874Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.Br J Cancer1990https://conductscience.org/library/papers/2183874PubMed
2178792A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP.Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/2178792PubMed
2155064Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer.Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/2155064PubMed
2114395Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts.Jpn J Cancer Res1990https://conductscience.org/library/papers/2114395PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6366128

GET https://conductscience.org/api/papers/v1/6366128/authors